Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.

ABSTRACT:

Unlabelled

Ixabepilone is an epothilone B analogue with activity in a variety of solid malignancies, including prostate cancer. The main dose-limiting toxicity of ixabepilone is myelosuppression when administered by using an every 3-week schedule. Here we evaluate the activity of a weekly ixabepilone in men with metastatic castrate-resistant prostate cancer to minimize hematologic toxicity.

Purpose

BMS-247550 (ixabepilone) is an epothilone B analogue with activity in taxane-resistant cancer cell lines. Here we report the activity and toxicity of ixabepilone, administered by using a weekly schedule, in men with metastatic castrate-resistant prostate cancer (CRPC).

Experimental design

Patients with metastatic CRPC received ixabepilone at 20 mg/m(2) intravenous weekly x

SUBMITTER: Liu G 

PROVIDER: S-EPMC3535436 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature